Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
Sensei Biotherapeutics Stock Analysis & Ratings
SNSE Stock Chart & Stats
Day’s Range$1.62 - $1.74
52-Week Range$1.45 - $15.12
Previous Close$1.6
Volume225.24K
Average Volume (3M)79.31K
Market Cap$52.07M
P/E Ratio-1.4
Beta0.79
Next EarningsAug 03, 2022
EPS Forecast-$0.4
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$5.00
Smart Score3
EPS (TTM)-1.20
Sensei Biotherapeutics News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNSE FAQ
What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $1.45 and its highest was $15.12 in the past 12 months.
What is Sensei Biotherapeutics’s market cap?
Sensei Biotherapeutics’s market cap is $52.07M.
What is Sensei Biotherapeutics’s price target?
The average price target for Sensei Biotherapeutics is $5.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 194.12% Increase from the current price of $1.7.
The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 194.12% Increase from the current price of $1.7.
What do analysts say about Sensei Biotherapeutics?
Sensei Biotherapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
When is Sensei Biotherapeutics’s upcoming earnings report date?
Sensei Biotherapeutics’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
How were Sensei Biotherapeutics’s earnings last quarter?
Sensei Biotherapeutics released its earnings results on May 10, 2022. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.05.
Is Sensei Biotherapeutics overvalued?
According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued.
Does Sensei Biotherapeutics pay dividends?
Sensei Biotherapeutics does not currently pay dividends.
What is Sensei Biotherapeutics’s EPS estimate?
Sensei Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sensei Biotherapeutics have?
Sensei Biotherapeutics has 30,630,000 shares outstanding.
What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
Sensei Biotherapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went up 9.804%.
Which hedge fund is a major shareholder of Sensei Biotherapeutics?
Among the largest hedge funds holding Sensei Biotherapeutics’s share is Moore Capital Management LP. It holds Sensei Biotherapeutics’s shares valued at N/A.
---
Sensei Biotherapeutics Stock Analysis
Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Price Target
$5.00
Moderate Buy▲(194.12% Upside)
Analyst Forecast
Moderate Buy
Average Price Target: $5.00
Blogger Sentiment
Bullish
SNSE Sentiment 100% Sector Average 71%
Hedge Fund Holdings
▼ Decreased
By 49.3K Shares Last Quarter.
Insider Transactions
▲ Bought Shares
Worth $332.2K over the Last 3 Months
Retail Investors
Very Negative
Last 7 Days ▼ 1.0% Last 30 Days ▼ 3.3%
News Sentiment
N/A
Currently Not Enough Data Available
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.31%
12-Months-Change
Fundamentals
Return on Equity
-45.31%
Trailing 12-Months
Asset Growth
615.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sensei Biotherapeutics
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.
---
---